Drug company Glenmark Pharmaceuticals announced on Monday that it has reduced the price of its antiviral drug Favipiravir, under the brand name FabiFlu, for treating patients with mild to moderate COVID-19, by 27 percent to as much as ₹75 per tablet.
Last month, Glenmark Pharmaceuticals launched FabiFlu at a price of approximately ₹103 per tablet.
Glenmark reported a 27 per cent price cut for FabiFlu in a regulatory filing. The latest retail maximum price (MRP) is only ₹75 per tab, he said.
“The price reduction was made possible by the benefits gained from higher yields and a better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark’s facilities in India, whose benefits are passed on to patients in the country,” the filing said.